Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
The improved prognosis and increased expected lifetime among long-term survivors of childhood malignancies have made these patients especially sensitiveto the late toxicity of cancer therapy and prone to secondary malignancies. Recently, new strategies aiming to protect against cancer treatment toxicity have been developed, including the drug amifostine (Ethyol), which is suggested to protect normal tissues from the toxic effects of radiation and cytotoxic agents. In the present study, the possible protective effect of amifostine against toxicity induced by a single injection of doxorubicin (3 mg/kg) in immature rats was evaluated. Specifically, we evaluated the protection against long-term toxicity and the effects of amifostine on growing immature tissues. Amifostine (50-200 mg/kg) given 15 min before doxorubicin had a significant protective effect against doxorubicin-induced early alopecia in young rats. Significant protection against cataract formation was obtained by the use of low-dose amifostine (50 mg/kg). However, amifostine did not protect young rats against the late toxic effect of doxoubicin on linear growth, body weight, plasma leptin levels, and heart or testicular tissue. Worrisome, and in contrast to earlier studies in adult rats, an increased doxorubicin toxicity actually was observed and mortality was increased when the higher doses of amifostine (100-200 mg/kg) were used. The present results suggest that more data from growing immature animal models are needed to analyze the safety of amifostine treatment and its mechanisms of action before wider clinical use of this drug in pediatric cancer patients is recommended.
Jahnukainen
K
K
Pediatric Endocrinology Unit, Karolinska Institute, Karolinska Hospital, 171 76 Stockholm, Sweden. Kirsi.Jahnukainen@hus.fi
Jahnukainen
T
T
Salmi
T T
TT
Svechnikov
K
K
Eksborg
S
S
Söder
O
O
D000367:Age Factors; D000505:Alopecia / Q000139:chemically induced / Q000517:prevention & control*; D004999:Amifostine / Q000494:pharmacology*; D000818:Animals; D000833:Animals, Suckling; D000903:Antibiotics, Antineoplastic / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D002386:Cataract / Q000139:chemically induced / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity*; D005260:Female; D006321:Heart / Q000187:drug effects; D020738:Leptin / Q000097:blood; D008297:Male; D009206:Myocardium / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013733:Testicular Diseases / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D013737:Testis / Q000187:drug effects / Q000473:pathology; D013739:Testosterone / Q000097:blood
D000903:Antibiotics, Antineoplastic; D020738:Leptin; D013739:Testosterone; D004317:Doxorubicin; D004999:Amifostine